← Back to Treatments

DHIVY

CARBIDOPA LEVODOPA

Manufacturer: Avion Pharmaceuticals, LLC

Indicated for:
X-linked reticulate pigmentary disorderPostencephalitic parkinsonismRare parkinsonian syndrome due to intoxicationDystonia-parkinsonism-hypermanganesemia syndrome

FDA-Approved Indications (4)

indicated for the treatment of Parkinson's disease

Population: all ages

indicated for the treatment of post-encephalitic parkinsonism

Population: all ages

indicated for the treatment of symptomatic parkinsonism that may follow carbon monoxide intoxication

Population: all ages

indicated for the treatment of symptomatic parkinsonism that may follow manganese intoxication

Population: all ages

Indications & Usage

1 INDICATIONS AND USAGE DHIVY is indicated for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. DHIVY is a combination of carbidopa (an aromatic amino acid decarboxylation inhibitor) and levodopa (an aromatic amino acid) indicated for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication ( 1 )

💙 Support Programs

View all →
DHIVY
Avion Pharmaceuticals, LLC

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.